(Q30794443)

26 June 2017

title

Evaluation of the cohort size in phase I dose escalation trials based on laboratory data (English)

1 reference

26 June 2017

Evaluation of the Cohort Size in Phase I Dose Escalation Trials Based on Laboratory Data (English)

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

3 January 2024

main subject

phase I clinical trial

0 references

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

3 January 2024

author name string

Camilla Buöen

1

1 reference

26 June 2017

Sture Holm

2

1 reference

26 June 2017

Mikael S. Thomsen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12751268

3 January 2024

language of work or name

1 reference

1 May 2003

1 reference

full work available at URL

26 June 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1177%2F0091270003252243

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

https://accp1.onlinelibrary.wiley.com/doi/pdf/10.1177/0091270003252243

3 January 2024

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

The Journal of Clinical Pharmacology

3 January 2024

published in

1 reference

26 June 2017

volume

43

1 reference

26 June 2017

issue

5

1 reference

26 June 2017

page(s)

470-476

1 reference

Estimating the starting dose for entry into humans: principles and practice

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Methodologic guidelines for the design of high-dose chemotherapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Learning from previous responses in phase I dose-escalation studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Serum transaminase elevations as indicators of hepatic injury following the administration of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Criteria of drug-induced liver disorders. Report of an international consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Transaminase elevation on placebo during phase I trials: prevalence and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Laboratory data in healthy volunteers: reference values, reference changes, screening and laboratory adverse event limits in Phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Why use placebos in clinical trials? A narrative review of the methodological literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Design and analysis of phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Design and analysis issues for crossover designs in phase I clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Clinical cross-over trials in phase I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

A novel Bayesian decision procedure for early-phase dose-finding studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Early clinical experience with the novel NMDA receptor antagonist CNS 5161.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

The placebo effect in healthy volunteers: influence of experimental conditions on physiological parameters during phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Adverse nondrug reactions: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003252243

Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectives

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

Critical limits to define a lab adverse event during phase I studies: a study in 1134 subjects

3 January 2024

8

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

Data on placebo in healthy volunteers: impact of experimental conditions on safety, and on laboratory and physiological variables during phase I trials

3 January 2024

13

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

Elevation of liver enzymes in multiple dose trials during placebo treatment: are they predictable?

3 January 2024

14

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

Effect of hospitalisation on liver enzymes in healthy subjects

3 January 2024

16

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects

3 January 2024

32

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

Pharmacodynamics and pharmacokinetics of DMP 728, a platelet GPIIb/IIIa antagonist, in healthy subjects

3 January 2024

33

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

Adverse events in phase-I studies: a report in 1015 healthy volunteers

3 January 2024

37

1 reference

https://api.crossref.org/works/10.1177/0091270003252243

3 January 2024

Identifiers

1 reference

26 June 2017

1 reference